

ANALYSIS OF THE IMPACT OF THE OMALIZUMAB SHORTAGE IN THE ALLERGY DEPARTMENT

I. GARCÍA MASEGOSA¹, R. GUZMÁN LAIZ¹, R. AÑEZ CASTAÑO¹, A. HERREROS FERNÁNDEZ¹, P. FERNÁNDEZ-VILLACAÑAS FERNÁNDEZ¹, P. ORTIZ FERNÁNDEZ¹, M.A. MEROÑO SAURA¹, C. CABALLERO REQUEJO¹, E. URBIETA SANZ².
¹HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA, PHARMACY, MURCIA, SPAIN.

4CPS-093

1. Background and importance

- ✓ Omalizumab: humanized monoclonal antibody that reduces the amount of free IgE available to trigger the allergic cascade.

3. Materials and methods



- ✓ Stockout period: July-September 2024.

4. Results

- ✓ 71 patients.
- ✓ 51/71 required medication during shortage.

2. Aim and objectives

- ✓ Analyze the impact of the omalizumab shortage on the allergy department, and measures taken to control it.



5. Conclusion and relevance



Stock-outs are a therapeutic challenge for the multidisciplinary team caring for the patient. Stock-outs have made possible to re-evaluate treatments and optimize therapy.